Literature DB >> 11053904

In vitro susceptibility to itraconazole, clotrimazole, ketoconazole and terbinafine of 100 isolates of Trichophyton rubrum.

B Fernández-Torres1, H Vázquez-Veiga, X Llovo, M Pereiro, J Guarro.   

Abstract

BACKGROUND: A reference method for dermatophyte in vitro susceptibility testing is lacking. With the advent of new antimycotics, susceptibility testing has received increasing attention as an important laboratory tool for aiding the selection of appropriate drug therapy.
METHODS: One hundred strains of Trichophyton rubrum were tested against four antifungal agents, itraconazole, clotrimazole, ketoconazole and terbinafine, by using a modification of the proposed standard M38-P of the National Committee for Clinical Laboratory Standards and two types of standardized inocula, 1.4 x 10(4) and 5 x 10(3) CFU/ml.
RESULTS: Terbinafine was revealed to be the most effective antifungal drug. Of the three azole derivatives tested, clotrimazole showed the highest antifungal activity, while the minimum inhibitory concentrations (MICs) of itraconazole and ketoconazole were similar. Inoculum size did not affect the MIC of any of the antifungal agents tested.
CONCLUSION: Our preliminary data provide promising results for the development of a reference method for dermatophyte susceptibility testing based on the microdilution technique, although more dermatophytes should be tested and the method evaluated in different laboratories. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11053904     DOI: 10.1159/000007319

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  8 in total

1.  In vitro activities of 10 antifungal drugs against 508 dermatophyte strains.

Authors:  B Fernández-Torres; A J Carrillo; E Martín; A Del Palacio; M K Moore; A Valverde; M Serrano; J Guarro
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

2.  Collaborative evaluation of optimal antifungal susceptibility testing conditions for dermatophytes.

Authors:  Belkys Fernández-Torres; Francisco J Cabañes; Alfonso J Carrillo-Muñoz; Alexandre Esteban; Isabel Inza; Lourdes Abarca; Josep Guarro
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

3.  Use of the sensititre colorimetric microdilution panel for antifungal susceptibility testing of dermatophytes.

Authors:  I Pujol; J Capilla; B Fernández-Torres; M Ortoneda; J Guarro
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

4.  Comparison of in vitro activities of 17 antifungal drugs against a panel of 20 dermatophytes by using a microdilution assay.

Authors:  Bertrand Favre; Bettina Hofbauer; Kwang-Soo Hildering; Neil S Ryder
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

5.  Intra- and interlaboratory study of a method for testing the antifungal susceptibilities of dermatophytes.

Authors:  M A Ghannoum; V Chaturvedi; A Espinel-Ingroff; M A Pfaller; M G Rinaldi; W Lee-Yang; D W Warnock
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

6.  Biological, biochemical, and molecular characterization of a new clinical Trichophyton rubrum isolate resistant to terbinafine.

Authors:  Colin S Osborne; Ingrid Leitner; Bettina Hofbauer; Ceri A Fielding; Bertrand Favre; Neil S Ryder
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

7.  Evaluation of broth microdilution antifungal susceptibility testing conditions for Trichophyton rubrum.

Authors:  D A Santos; J S Hamdan
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

8.  Comparison of the in vitro activities of newer triazoles and established antifungal agents against Trichophyton rubrum.

Authors:  Shuwen Deng; Chao Zhang; Seyedmojtaba Seyedmousavi; Shuang Zhu; Xin Tan; Yiyang Wen; Xin Huang; Wenzhi Lei; Zhaojing Zhou; Wenjie Fang; Shuaishuai Shen; Danqi Deng; Weihua Pan; Wanqing Liao
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.